Clinical Trials Logo

Ocular Surface Disease clinical trials

View clinical trials related to Ocular Surface Disease.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06013436 Completed - Dry Eye Clinical Trials

AST Combined With 0.05% Cyclosporin Eye Drop Improve Corneal Nerve Density in Patients With SS Dry Eye

AST/SS
Start date: June 1, 2022
Phase:
Study type: Observational

The objective of the present study was to evaluate the efficacy of autologous serum tears combined with 0.05% cyclosporin eye drop in treating Sjögren's syndrome dry eye and their effect on corneal nerves. We assessed the impact of 12-week AST combined with 0.05% cyclosporin eye drop treatment on signs, symptoms, and sub-basal nerve density (SND) in patients with dry eyes related to Sjogren's syndrome.

NCT ID: NCT05832996 Completed - Clinical trials for Ocular Surface Disease

Cool vs Room-temperature Artificial Tears

Start date: March 1, 2022
Phase: Phase 4
Study type: Interventional

Background and Objective: To evaluate the efficacy of cooled versus room temperature artificial tears in reducing post intravitreal injection (IVI) ocular discomfort. Patients and Methods: Patients receiving IVI were randomized to either cooled or room temperature tears intervention groups. Both groups rated their ocular discomfort following IVI before intervention and again after administration of cooled or room temperature tears.

NCT ID: NCT05528016 Completed - Dry Eye Clinical Trials

Short and Long-term Results of Skin Versus Skin Plus Orbicularis Resection Blepharoplasty

Start date: May 1, 2021
Phase: N/A
Study type: Interventional

This study aims to evaluate the short and long-term effects of skin-only and skin+muscle excision blepharoplasty on corneal nerves, dry eye parameters, meibomian glands, and eyebrow position.

NCT ID: NCT05319470 Completed - Glaucoma Clinical Trials

Ocular Surface Disease and IOP Monitoring With Travoprost Without Conservatives

Start date: March 15, 2022
Phase:
Study type: Observational [Patient Registry]

Primary objective of this study is to study the efficacy of travoprost without preservatives in the treatment of glaucoma patients and to monitor the ocular surface.

NCT ID: NCT04960696 Completed - Dry Eye Clinical Trials

Effect on Ocular Surface Symptoms of Online Education

Start date: April 14, 2021
Phase:
Study type: Observational [Patient Registry]

retrospective, observational study.

NCT ID: NCT04949295 Completed - Dry Eye Clinical Trials

Evaluation of Ocular Surface in Hemodialysis Patients by Ocular Surface Analyzer

Start date: January 1, 2021
Phase:
Study type: Observational

We clinically observed that some hemodialysis patients had corneal epithelial dryness, shedding, edema, and persistent epithelial nonunion after ocular surgery, which seriously affected the effect of surgery, and it is necessary to study the ocular surface characteristics of hemodialysis patients. In this study, we examined the ocular surface and analyzed and investigated the characteristics of the ocular surface in hemodialysis patients to provide a basis for ocular surface intervention or treatment in hemodialysis patients before ocular surgery in clinical practice.

NCT ID: NCT04918823 Completed - Clinical trials for Ocular Surface Disease

Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% on Application of PROSE Devices for Management of Patients With Ocular Surface Disease

Start date: July 15, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this prospective observational pilot study is to evaluate the tolerability and safety of RESTASIS (cyclosporine ophthalmic solution 0.05%) when added to the PROSE (Prosthetic Replacement of the Ocular Surface Ecosystem) lens reservoir in patients with ocular surface disease (OSD). Secondary endpoints include early (1-month) efficacy data for ocular signs and symptoms.

NCT ID: NCT04828057 Completed - Clinical trials for Primary Open Angle Glaucoma

Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting

Start date: September 1, 2021
Phase:
Study type: Observational

The primary objective of this study is to assess the effectiveness of Tafluprost / Timolol in controlling ocular hypertension, as measured by mean change in intra-ocular pressure (IOP) from baseline to after 6 months of treatment from initiation, in patients with open angle glaucoma (OAG) or ocular hypertension (OHT), who do not respond sufficiently to initial topical treatment, in routine clinical practice.

NCT ID: NCT04812951 Completed - Clinical trials for Ocular Surface Disease

Cyclosporine 0.1% Eye Drops as Prophylactic Treatment In Cataract Surgery

CSA2020
Start date: February 17, 2021
Phase: Early Phase 1
Study type: Interventional

Use of Cyclosporine 0.1% Eye Drops as Prophylactic Treatment in cataract Surgery

NCT ID: NCT04673604 Completed - Glaucoma Clinical Trials

From Preserved, to Preservative-free Cyclosporine 0.1% Enhanced Triple Glaucoma Therapy

Start date: May 6, 2018
Phase: N/A
Study type: Interventional

There is a lack of evidence on the impact of switching from a combined preserved anti-glaucoma regimen to a preservative-free (PF) one, while employing sufficiently robust OSD metrics. The investigators have therefore carried out a single center, prospective, crossover investigation to compare the 6-month effect of switching well controlled open-angle glaucoma patients with at least moderate glaucoma therapy-related ocular surface disease from preserved to triple preservative-free therapy with and without cyclosporine 0.1% dosed in the evening.